Literature DB >> 7050158

Enzyme-linked immunosorbent assay for measurement of antibody to type III group B streptococci.

R A Polin, S D Douglas, D L Kasper, C J Baker.   

Abstract

Neonates at risk for fulminant type III, group B streptococcal (III GBS) infection are those who lack antibody to the capsular polysaccharide. A newly developed enzyme-linked immunosorbent assay (ELISA) was compared with a standard radioactive antigen-binding assay (RABA) for quantitation of III GBS antibody in human sera. Although there was a significant correlation between the ELISA and RABA (r = 0.81; P less than 0.001) in general, the ELISA detected antibody both to core and native antigens of III GBS, whereas the RABA detected antibody to native polysaccharide exclusively. The results of the two assays were discordant when sera which had only high native or core antibody (not both) were assessed. Although the ELISA was reproducible and required less than 1 microliter of serum, interpretation of data obtained by the assay should be viewed with caution since only antibody to native III GBS has been correlated with human immunity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7050158      PMCID: PMC272240          DOI: 10.1128/jcm.15.6.991-993.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Group B streptococcal neonatal and infant infections.

Authors:  R A Franciosi; J D Knostman; R A Zimmerman
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

2.  Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants.

Authors:  C J Baker; F F Barrett; R C Gordon; M D Yow
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

3.  Enzyme-linked immunosorbent assay for group B streptococcal antibodies.

Authors:  N S Rote; N L Taylor; A O Shigeoka; J R Scott; H R Hill
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

4.  Radioimmunoassay for measuring antibodies specific for group B streptococcal types Ia, Ib, Ic, II, and III.

Authors:  H W Wilkinson; W L Jones
Journal:  J Clin Microbiol       Date:  1976-05       Impact factor: 5.948

5.  Chicken embryo model for type III group B beta-hemolytic streptococcal septicemia.

Authors:  J Tieffenberg; L Vogel; R R Kretschmer; D Padnos; S P Gotoff
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

6.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.

Authors:  C J Baker; D L Kasper
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

7.  Human immunity to group B streptococci measured by indirect immunofluorescence: correlation with protection in chick embryos.

Authors:  L C Vogel; R R Kretschmer; K M Boyer; D M Padnos; C A Gadzala; S P Gotoff
Journal:  J Infect Dis       Date:  1979-11       Impact factor: 5.226

8.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

9.  The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus.

Authors:  M S Edwards; A Nicholson-Weller; C J Baker; D L Kasper
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  Immunodeterminant specificity of human immunity to type III group B streptococcus.

Authors:  D L Kasper; C J Baker; R S Baltimore; J H Crabb; G Schiffman; H J Jennings
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

View more
  2 in total

1.  In vitro lymphocyte proliferation in response to type III group B streptococci.

Authors:  M A Lillie; C S Cody; S D Douglas; R A Polin
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

2.  Aspergillus fumigatus-specific antibodies in allergic bronchopulmonary aspergillosis and aspergilloma: evidence for a polyclonal antibody response.

Authors:  W Brummund; A Resnick; J N Fink; V P Kurup
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.